Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.10T
Market cap1.10T
Price-Earnings ratio
39.96
Price-Earnings ratio39.96
Dividend yield
0.55%
Dividend yield0.55%
Average volume
2.58M
Average volume2.58M
High today
$1,188.89
High today$1,188.89
Low today
$1,162.93
Low today$1,162.93
Open price
$1,171.01
Open price$1,171.01
Volume
1.36M
Volume1.36M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$712.05
52 Week low$712.05

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,164.64, giving the company a market capitalization of 1.1T. It carries a P/E multiple of 39.96 and pays a dividend yield of 0.55%.

On 2026-08-28, Eli Lilly(LLY) stock traded between a low of $1,162.93 and a high of $1,188.89. Shares are currently priced at $1,164.64, which is +0.1% above the low and -2.0% below the high.

The Eli Lilly(LLY)'s current trading volume is 1.36M, compared to an average daily volume of 2.58M.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

LLY News

TIME 43m
Mounjaro Is Now Approved to Lower the Risk of Heart Events - Time Magazine

...

Mounjaro Is Now Approved to Lower the Risk of Heart Events - Time Magazine
TipRanks 9h
Eli Lilly announces FDA approval of Mounjaro to reduce cardiovascular risk

Eli Lilly (LLY) and Company announced that the U.S. FDA approved Mounjaro, a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse car...

TipRanks 1d
Eli Lilly Stock Pulls Back After Hitting Record High

Shares of Eli Lilly (LLY) are pulling back after hitting an all-time high. The pharmaceutical company’s stock has dropped 4% in the past week after reaching a r...

Analyst ratings

82%

of 33 ratings
Buy
81.8%
Hold
12.1%
Sell
6.1%

More LLY News

TipRanks 1d
Lilly Targets China’s Obesity Market With New Phase 3 Oral Orforglipron Trial

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The phase 3 study “A Phase 3, Randomized, Double-Blind Study to Investigate th...

TipRanks 1d
Lilly’s Brenipatide Steps Into Phase 3: A New Long-Term Play in Depression Care

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 3 RENEW-MDD-2 study from Eli Lilly And Company tests brenipatide as...

Simply Wall St 1d
Eli Lilly Says Zepbound Cuts Healthcare Costs For Adults Over 55

Eli Lilly (NYSE: LLY) reported new independent real-world evidence that its obesity treatment Zepbound (tirzepatide) is linked to lower overall healthcare costs...

Eli Lilly Says Zepbound Cuts Healthcare Costs For Adults Over 55
TipRanks 2d
Lilly Quietly Expands Its Alzheimer’s Pipeline With New Early-Stage Trial

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) has launched a Phase 1 trial titled “A Placebo-Control...

TipRanks 2d
Eli Lilly Stock in Focus as Alzheimer Blood Test Gets FDA Approval

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s (LLY) new blood test that helps to identify signs of Alzheimer’s disease in people aged 55...

Nasdaq 2d
Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.

Key Points Obesity drugs like Mounjaro and Zepbound could help the drugmaker power ahead for years. Its Alzheimer’s drug Kisunla and broad pipeline add anothe...

Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.
The Motley Fool 2d
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

The Fidelity MSCI Health Care Index ETF (FHLC +0.47%) provides broad, low-cost exposure to the entire healthcare sector, whereas the VanEck Pharmaceutical ETF (...

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.